Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Malonyl-CoA-acyl carrier protein transacylase, mitochondrial (MCAT)
- Target
- MCAT
- Molecular classification
- Enzyme, Transferase (specifically: acyltransferase), Mitochondrial protein
01
Overview
Malonyl-CoA-acyl carrier protein transacylase, mitochondrial (MCAT) is an enzyme that catalyzes the transfer of the malonyl group from malonyl-CoA to the acyl carrier protein (ACP) during mitochondrial fatty acid synthesis. This reaction is a critical step for the initiation and elongation of fatty acid chains within mitochondria, distinct from cytoplasmic fatty acid biosynthesis. MCAT is classified as an acyltransferase and is encoded by the MCAT gene in humans. It plays an essential role in mitochondrial lipid metabolism necessary for energy production, membrane biosynthesis, and overall mitochondrial function. Although not a common direct drug target, defects in MCAT function can contribute to metabolic and mitochondrial diseases.
- Other names
- MCATMalonyl-CoA-acyl carrier protein transacylase (mitochondrial)Mitochondrial malonyl CoA:ACP acyltransferaseMitochondrial malonyltransferase[Acyl-carrier-protein] malonyltransferase[Acyl-carrier-protein] S-malonyltransferaseMalonyl CoA:ACP acyltransferase (mitochondrial)fabDFASN2CNET62MCT1OPA15MTMCT
02
Mechanism of action
N/A (No targeted drugs documented; mechanistically, MCAT catalyzes the transfer of a malonyl group from malonyl-CoA to mitochondrial ACP, a step crucial in mitochondrial de novo fatty acid biosynthesis)
03
Biological functions
Fatty acid synthesisLipid metabolismTransfer of the malonyl group from malonyl-CoA to acyl carrier protein (ACP), a required step in mitochondrial fatty acid biosynthesis
04
Disease associations
Metabolic disordersMitochondrial dysfunctionPossibly neurodevelopmental disorders (based on gene mutation studies; MCAT gene is essential in mitochondrial fatty acid synthesis and related disorders have been reported)Other (no strong direct links to major diseases such as cancer or inflammation, but metabolic consequences could be far-reaching)
05
Safety considerations
Targeting MCAT could disrupt mitochondrial fatty acid synthesis, potentially causing cellular energy deficits, mitochondrial dysfunction, or metabolic disordersEssentiality for mitochondrial and cellular health may cause generalized toxicity if inhibited systemically
06
Interacting drugs
None well-documented (no direct drugs currently known to target MCAT specifically in clinical use or major publications as of the latest evidence)
07
Biomarkers
No well-established biomarkers for patient selection or efficacy monitoring directly related to MCAT
Beyond the preview
Go deeper on Malonyl-CoA-acyl carrier protein transacylase, mitochondrial (MCAT).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Malonyl-CoA-acyl carrier protein transacylase, mitochondrial (MCAT).